Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia

Ester Maria Orlandi, Chiara Elena, Elisa Bono

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalLeukemia and Lymphoma
DOIs
Publication statusAccepted/In press - Nov 28 2016

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia. / Orlandi, Ester Maria; Elena, Chiara; Bono, Elisa.

In: Leukemia and Lymphoma, 28.11.2016, p. 1-3.

Research output: Contribution to journalArticle

@article{0e81ab3fb9fc40449a4582f946d9dbe5,
title = "Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia",
author = "Orlandi, {Ester Maria} and Chiara Elena and Elisa Bono",
year = "2016",
month = "11",
day = "28",
doi = "10.1080/10428194.2016.1260127",
language = "English",
pages = "1--3",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia

AU - Orlandi, Ester Maria

AU - Elena, Chiara

AU - Bono, Elisa

PY - 2016/11/28

Y1 - 2016/11/28

UR - http://www.scopus.com/inward/record.url?scp=84997684138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997684138&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1260127

DO - 10.1080/10428194.2016.1260127

M3 - Article

AN - SCOPUS:84997684138

SP - 1

EP - 3

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -